Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2085)	1/7/2008 9:38:29 AM
From: Jibacoa	Respond to of 3722

CELG Is also reviewing its 2007 achievements and will provide its outlook for 2008 at the JPMorgan 26th Annual Healthcare Conference in Frisco. biz.yahoo.com The stock is above $51 & volume is over 2M bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2085)	3/24/2008 5:37:19 PM
From: Jibacoa	Respond to of 3722

BIIB needs to close its Dec 14 DG. Today the stock was up only 4.17% on volume of 3,329,962 which was below its ADV & it hasn't being doing well AHs, but that may change.<g> bigcharts.marketwatch.com It announced that in collaboration with scientists at the University of Arizona & Tufts, it reported in the Apr issue of Nature Neuroscience that in preclinical studies,the injections of neublastin promoted the regeneration of damaged sensory nerve cells and produced virtually complete, long-term restoration of sensory and motor function, which suggest that neublastin has potential for further development as a treatment for traumatic nerve injury. Neublastin acts selectively on sensory neurons. In previous preclinical studies it was shown to alleviate chronic pain associated with peripheral nerve injury. In a series of biochemical, molecular and electrophysiology studies, the researchers also demonstrated that neublastin promoted the regeneration of multiple classes of nerve cells back into the spinal cord and the re-establishment of functional connections with their spinal targets. BIIB is developing neublastin for use in treating peripheral nervous system diseases under an exclusive license from NsGene. (NsGene was established as a spin-off company from NeuroSearch in Dec 1999) The stock trades around 3.2xBV, has negligible LTD & has +CF around $4.30. With some good news it could get back to the $80 level.<g> bigcharts.marketwatch.com Bernard